Fate Therapeutics (FATE) EBT Margin (2012 - 2026)
Fate Therapeutics (FATE) reported EBT Margin of 2396.69% for Q1 2026, down 6741.0% on a YoY basis from 36.09% in Q1 2025, and down 0.95% quarter-over-quarter from 2374.07% in Q4 2025.
Fate Therapeutics (FATE) EBT Margin (2012 - 2026) Analysis & Trends
Fate Therapeutics has reported EBT Margin for 14 years, with the latest figure at 2396.69% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin fell 6741.0% year-over-year to 2396.69%; the trailing twelve-month figure through Mar 2026 stood at 2055.75% (down 67582.0% YoY), and the FY2025 full-year result was 2056.15%, down 64035.0% from the prior year.
- EBT Margin for Q1 2026 stood at 2396.69%, down from 2374.07% in the prior quarter.
- The five-year high for EBT Margin was 42.21% in Q1 2023, with the low at 6236.23% in Q2 2023.
- Historically, EBT Margin has averaged 1839.1% across 5 years, with a median of 1847.21% in 2025.
- Annual changes were most pronounced in 2023 — EBT Margin plunged 579226 bps — and 2024, when it jumped 564178 bps.
- Fate Therapeutics' EBT Margin stood at 138.74% in 2022, then sank by 1778 bps to 2605.07% in 2023, then fell by 19 bps to 3111.51% in 2024, then rose by 24 bps to 2374.07% in 2025, then retreated by 1 bps to 2396.69% in 2026.
- The last three EBT Margin figures came in at 2396.69% (Q1 2026), 2374.07% (Q4 2025), and 1847.21% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - | -2,396.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,396.69% |
| Dec 31, 2025 | -2,374.07% |
| Sep 30, 2025 | -1,847.21% |
| Jun 30, 2025 | -1,785.37% |
| Mar 31, 2025 | -2,329.28% |
| Dec 31, 2024 | -3,111.51% |
| Sep 30, 2024 | -1,559.50% |
| Jun 30, 2024 | -594.45% |
| Mar 31, 2024 | -2,437.35% |
| Dec 31, 2023 | -2,605.07% |
| Sep 30, 2023 | -2,396.19% |
| Jun 30, 2023 | -6,236.23% |
| Mar 31, 2023 | -42.21% |
| Dec 31, 2022 | -138.74% |
| Sep 30, 2022 | -564.74% |
| Jun 30, 2022 | -443.97% |
| Mar 31, 2022 | -402.13% |
| Dec 31, 2021 | -404.74% |
| Sep 30, 2021 | -381.96% |
| Jun 30, 2021 | -346.20% |